Marlene Milgram

Marlene Milgram serves as a key procurement professional within the National Institute on Drug Abuse (NIDA), supporting the agency’s mission to advance scientific research on substance use disorders through strategic acquisition of specialized scientific and technical services. She manages a diverse portfolio of contracts focused on translating laboratory findings into clinical and public health applications, overseeing procurements that enable cutting-edge neurobiological, behavioral, and epidemiological research. Her acquisitions primarily support research infrastructure, analytical instrumentation, and scientific consulting services critical to NIDA’s evidence-based policy and treatment development goals. Milgram maintains strong, sustained relationships with leading academic and research institutions including The McLean Hospital Corporation, the University of Maryland, Baltimore, the University of Miami, the University of Pittsburgh, and the Icahn School of Medicine at Mount Sinai. These partnerships reflect a preference for high-capacity research entities capable of delivering complex, multi-site studies, longitudinal data analysis, and translational neuroscience services. Her contracting patterns emphasize long-term, performance-based agreements that align with the iterative nature of NIH-funded research. Her procurement strategy reflects a balanced approach to socioeconomic participation, with nearly half of her awards structured as total small business set-asides under FAR 19.5, demonstrating a clear commitment to expanding opportunities for small businesses in the biomedical research ecosystem. While the majority of contracts remain open to all competitors, her consistent use of small business set-asides underscores support for innovation from emerging scientific vendors. Milgram’s primary NAICS focus areas include All Other Professional, Scientific, and Technical Services (541990) and Analytical Laboratory Instrument Manufacturing (334516), reflecting her specialization in procuring research instrumentation, data analytics platforms, and scientific consulting services. She frequently acquires precision laboratory equipment, pharmaceutical preparation technologies, and electronic maintenance services critical to NIDA’s experimental and clinical research infrastructure.